Svetomir N. Markovic

17.9k total citations · 2 hit papers
349 papers, 12.2k citations indexed

About

Svetomir N. Markovic is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Svetomir N. Markovic has authored 349 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Oncology, 145 papers in Immunology and 89 papers in Molecular Biology. Recurrent topics in Svetomir N. Markovic's work include Immunotherapy and Immune Responses (84 papers), Cancer Immunotherapy and Biomarkers (78 papers) and Lymphoma Diagnosis and Treatment (74 papers). Svetomir N. Markovic is often cited by papers focused on Immunotherapy and Immune Responses (84 papers), Cancer Immunotherapy and Biomarkers (78 papers) and Lymphoma Diagnosis and Treatment (74 papers). Svetomir N. Markovic collaborates with scholars based in United States, Italy and Belarus. Svetomir N. Markovic's co-authors include Luis F. Porrata, Lisa A. Kottschade, Stephen M. Ansell, David J. Inwards, Wendy K. Nevala, Ivana N. Micallef, Shernan G. Holtan, Roxana Dronca, Douglas J. Creedon and Patrick B. Johnston and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Svetomir N. Markovic

333 papers receiving 11.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

2019 594 citations Svetomir N. Markovic, Grzegorz S. Nowakowski et al. profile →
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

2008 534 citations Sandra J. Lee, Vernon K. Sondak et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Svetomir N. Markovic United States	60	6.9k	4.0k	3.4k	1.7k	1.5k	349	12.2k
Claudio Tripodo Italy	55	2.8k 0.4×	4.6k 1.2×	3.0k 0.9×	1.4k 0.8×	843 0.5×	245	10.5k
Rosemarie Mick United States	72	6.2k 0.9×	3.2k 0.8×	3.5k 1.1×	1.5k 0.9×	2.6k 1.7×	265	14.4k
David R. Spriggs United States	62	4.9k 0.7×	3.0k 0.7×	4.2k 1.3×	835 0.5×	1.9k 1.2×	230	13.0k
Walter J. Urba United States	55	5.9k 0.9×	5.5k 1.4×	2.6k 0.8×	1.1k 0.6×	1.7k 1.1×	223	10.7k
Massimo Aglietta Italy	58	7.1k 1.0×	3.0k 0.7×	3.6k 1.1×	1.6k 0.9×	2.8k 1.8×	397	14.5k
Célèste Lebbé France	57	12.8k 1.9×	4.4k 1.1×	4.4k 1.3×	1.6k 0.9×	2.7k 1.8×	543	18.0k
Mitsune Tanimoto Japan	58	5.2k 0.8×	2.5k 0.6×	4.2k 1.2×	1.5k 0.9×	4.5k 2.9×	525	13.7k
Douglas B. Johnson United States	59	9.8k 1.4×	4.0k 1.0×	4.6k 1.4×	843 0.5×	2.4k 1.5×	293	14.1k
Mario E. Lacouture United States	67	9.5k 1.4×	1.5k 0.4×	3.2k 1.0×	1.4k 0.8×	3.1k 2.0×	375	15.1k
Steven T. Rosen United States	61	5.7k 0.8×	3.3k 0.8×	4.5k 1.3×	6.5k 3.7×	1.3k 0.9×	423	15.9k

Countries citing papers authored by Svetomir N. Markovic

Since Specialization

Citations

This map shows the geographic impact of Svetomir N. Markovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svetomir N. Markovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svetomir N. Markovic more than expected).

Fields of papers citing papers by Svetomir N. Markovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Svetomir N. Markovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svetomir N. Markovic. The network helps show where Svetomir N. Markovic may publish in the future.

Co-authorship network of co-authors of Svetomir N. Markovic

This figure shows the co-authorship network connecting the top 25 collaborators of Svetomir N. Markovic. A scholar is included among the top collaborators of Svetomir N. Markovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svetomir N. Markovic. Svetomir N. Markovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brewer, Jerry D., et al.. (2023). Cytokine Storm Due to Intralesional Intelukin-2 Therapy for Cutaneous In-Transit Melanoma. Dermatologic Surgery. 49(12). 1198–1199.

Weber, Jeffrey S., Waqar Haque, Svetomir N. Markovic, et al.. (2023). 1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma. Annals of Oncology. 34. S657–S658. 1 indexed citations

Porrata, Luis F., Stephen M. Ansell, Ivana N. Micallef, et al.. (2023). Day 100 Natural Killer Cell/CD14+HLA‐DR^DIM ratio and survival in lymphoma post‐autologous peripheral blood hematopoietic stem cell transplantation. Clinical Transplantation. 38(1). e15211–e15211. 1 indexed citations

Smith, Katherine E., Sarah M. Jenkins, Anastasios Dimou, et al.. (2023). Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.. Journal of Clinical Oncology. 41(16_suppl). 9538–9538. 1 indexed citations

Buglioni, Alessia, Ruifeng Guo, Kandelaria M. Rumilla, et al.. (2023). An Unexpected Diagnosis Uncovered by Quantitative Molecular Findings: A Case Report. Journal of the National Comprehensive Cancer Network. 21(8). 787–791. 1 indexed citations

Leontovich, Alexey A., Raymond M. Moore, Wendy K. Nevala, et al.. (2022). Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade. Cancer Research Communications. 2(2). 78–89. 6 indexed citations

Hieken, Tina J., Amy E. Glasgow, Elizabeth Ann L. Enninga, et al.. (2020). Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort. Journal of Women s Health. 29(9). 1160–1167. 23 indexed citations

Wang, Lei, Sara J. Felts, Virginia P. Van Keulen, et al.. (2018). Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Research. 78(15). 4411–4423. 24 indexed citations

Jakub, James W., Wendy K. Nevala, Trace Christensen, et al.. (2017). Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation. Frontiers in Immunology. 8. 358–358. 68 indexed citations

10.

Nevala, Wendy K., Sarah A. Buhrow, Daniel J. Knauer, et al.. (2016). Antibody-Targeted Chemotherapy for the Treatment of Melanoma. Cancer Research. 76(13). 3954–3964. 22 indexed citations

11.

Witzig, Thomas E., Craig B. Reeder, Jing Han, et al.. (2015). The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 126(3). 328–335. 83 indexed citations

12.

Grotz, Travis E., Lisa A. Kottschade, Emily S. Pavey, Svetomir N. Markovic, & James W. Jakub. (2013). Adjuvant GM-CSF Improves Survival in High-risk Stage IIIC Melanoma. American Journal of Clinical Oncology. 37(5). 467–472. 24 indexed citations

13.

Averbook, Bruce J., Sandra J. Lee, Keith A. Delman, et al.. (2013). Pediatric melanoma: Analysis of an international registry. Cancer. 119(22). 4012–4019. 53 indexed citations

14.

Chavan, Rahul N., et al.. (2013). Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity. Cancer Immunology Research. 2(3). 241–248. 27 indexed citations

15.

Takahashi, Rie, Svetomir N. Markovic, & Heidi Scrable. (2013). Dominant Effects of Δ40p53 on p53 Function and Melanoma Cell Fate. Journal of Investigative Dermatology. 134(3). 791–800. 30 indexed citations

16.

Kim, Kevin B., Jeffrey A. Sosman, John P. Fruehauf, et al.. (2011). BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology. 30(1). 34–41. 148 indexed citations

17.

Geng, Degui, Liqin Zheng, Ratika Srivastava, et al.. (2010). Amplifying TLR-MyD88 Signals within Tumor-Specific T Cells Enhances Antitumor Activity to Suboptimal Levels of Weakly Immunogenic Tumor Antigens. Cancer Research. 70(19). 7442–7454. 37 indexed citations

18.

Pires, Ana Elisabete, Ana C. Queirós, Luis F. Porrata, et al.. (2010). Treatment With Polyclonal Immunoglobulin During T-cell Reconstitution Promotes Naive T-cell Proliferation. Journal of Immunotherapy. 33(6). 618–625. 8 indexed citations

19.

Erickson, Lori A., Jeffrey L. Myers, Martín C. Mihm, Svetomir N. Markovic, & Mark R. Pittelkow. (2004). Malignant Basomelanocytic Tumor Manifesting as Metastatic Melanoma. The American Journal of Surgical Pathology. 28(10). 1393–1396. 37 indexed citations

20.

Mann, Eric, Svetomir N. Markovic, & Donna M. Murasko. (1989). Inhibition of Lymphocyte Recirculation by Murine Interferon: Effects of Various Interferon Preparations and Timing of Administration. Journal of Interferon Research. 9(1). 35–51. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact